Objective:

To explore the unique behaviors of PFAS in the body and the urgent need for new risk assessment models that accurately reflect their health impacts.

Key Findings:

• PFAS do not accumulate in fatty tissues like traditional pollutants; they interact with transporter proteins and phospholipids, leading to unique bioaccumulation patterns.
• Current risk models based on hydrophobicity and lipid affinity are inadequate for PFAS, necessitating a reevaluation of these frameworks.
• There is a significant unidentified fraction of organofluorine in biological samples, which varies by population and exposure levels, indicating gaps in current analytical methods.

Interpretation:

The unique properties of PFAS necessitate a reevaluation of risk assessment models to accurately reflect human exposure and health impacts, particularly in chronic exposure scenarios.

Limitations:

• Existing analytical methods do not fully account for unidentified organofluorine compounds, leading to potential underestimations of PFAS exposure.
• The variability in studies regarding unidentified fractions complicates the understanding of PFAS bioaccumulation and its health implications.

Conclusion:

A shift in research focus and methodology is essential to address the complexities of PFAS bioaccumulation and its health implications, highlighting the need for urgent action in this area.